• Skip to primary navigation
  • Skip to content
  • Skip to footer

BerGenBio

Selective AXL inhibitors

Header Right

Main navigation

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | TBNC
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
  • Media Centre
    • News
    • Events
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Contact
Home  /  Investors  /  Investor Relations Contacts

For Investor Relations Information Or Questions Please Contact:

Richard Godfrey

Chief Executive Officer

Phone: +47 559 61 159

Email: ir@bergenbio.com

Rune Skeie

Chief Financial Officer

Phone: +47 917 86 513‬

Email: rune.skeie@bergenbio.com

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs